GlassScriptPhysician profile
Thang Tran
NPI 1275514069
$7,964.95
in general payments reported to CMS, 2019-2025
21 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,826 · 2020: $570 · 2021: $1,150 · 2022: $905 · 2023: $1,071 · 2024: $1,296 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,919.13 | 2019-2025 | Botox |
| Ibsa Pharma INC. | $1,027.96 | 2021-2025 | Tirosint, Licart, Tirosint |
| Gilead Sciences, INC. | $835.20 | 2019-2025 | |
| Amarin Pharma, INC. | $701.72 | 2019-2022 | |
| Boston Scientific Corporation | $680.37 | 2019-2022 | |
| Allergan, INC. | $406.17 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $401.28 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $270.70 | 2021 | |
| Galderma Laboratories, L.P. | $261.01 | 2019-2023 | |
| Revance Therapeutics, INC. | $247.44 | 2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.19 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $141.17 | 2019 | |
| Edwards Lifesciences Corporation | $135.64 | 2022 | |
| Eisai INC. | $124.55 | 2025 | |
| Merck Sharp & Dohme LLC | $122.45 | 2023 | Verquvo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $121.08 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $106.08 | 2019 | |
| Inspire Medical Systems, INC. | $99.22 | 2023 | Inspire |
| Genentech USA, INC. | $78.81 | 2020-2021 | |
| Merz North America, INC. | $70.79 | 2020-2025 | |
| Glaxosmithkline, LLC. | $24.99 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thang Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.